Literature DB >> 16917759

The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II.

P J Talmud1, J A Cooper, H Hattori, I P Miller, G J Miller, S E Humphries.   

Abstract

AIMS/HYPOTHESIS: We sought to establish the relationship between plasma apolipoprotein A-V (APOA5, previously known as apoA-V) and triglyceride levels and to determine the impact of the APOA5 genotype on APOA5 levels and development of type 2 diabetes in a 15-year follow-up study of healthy UK men.
MATERIALS AND METHODS: APOA5 -1131T>C and S19W genotypes were determined in 2,490 men, of whom 145 subsequently developed type 2 diabetes. In a subset of 299 men, we also determined APOA5 levels.
RESULTS: Plasma APOA5 levels positively correlated with triglycerides (r=0.18, p<0.002) and were not different in men who subsequently developed type 2 diabetes compared with healthy men (p=0.7). Carriers of either APOA5 W19 or -1131C had, as expected, higher plasma triglycerides. However, while W19 carriers had significantly higher APOA5 levels (p=0.0003), APOA5 levels were not associated with -1131T>C (p=0.63), reinforcing the idea that the reported -1131C association with triglycerides levels is due to linkage disequilibrium with variants in the APOC3 gene, and not due to the direct effect on APOA5 levels. Overall no effect of APOA5 -1131T>C or S19W was found on type 2 diabetes risk. CONCLUSIONS/
INTERPRETATION: In contrast to animal studies, in man, plasma APOA5 positively correlates with plasma triglyceride levels. In prospective analysis, with the caveat that numbers were small, APOA5 genotypes do not appear to have an impact on risk of development of type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16917759     DOI: 10.1007/s00125-006-0387-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  11 in total

Review 1.  Give me A5 for lipoprotein hydrolysis!

Authors:  Martin Merkel; Joerg Heeren
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

2.  A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration.

Authors:  Mitsuaki Ishihara; Takeshi Kujiraoka; Tadao Iwasaki; Makoto Nagano; Mayumi Takano; Jun Ishii; Masahiro Tsuji; Hajime Ide; Irina P Miller; Norman E Miller; Hiroaki Hattori
Journal:  J Lipid Res       Date:  2005-06-16       Impact factor: 5.922

3.  Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease.

Authors:  G J Miller; K A Bauer; S Barzegar; J A Cooper; R D Rosenberg
Journal:  Thromb Haemost       Date:  1996-05       Impact factor: 5.249

4.  Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides.

Authors:  Philippa J Talmud; Emma Hawe; Steve Martin; Michael Olivier; George J Miller; Edward M Rubin; Len A Pennacchio; Steve E Humphries
Journal:  Hum Mol Genet       Date:  2002-11-15       Impact factor: 6.150

5.  Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels.

Authors:  Len A Pennacchio; Michael Olivier; Jaroslav A Hubacek; Ronald M Krauss; Edward M Rubin; Jonathan C Cohen
Journal:  Hum Mol Genet       Date:  2002-11-15       Impact factor: 6.150

6.  Variation in the UCP2-UCP3 gene cluster predicts the development of type 2 diabetes in healthy middle-aged men.

Authors:  David R Gable; Jefferey W Stephens; Jackie A Cooper; George J Miller; Steve E Humphries
Journal:  Diabetes       Date:  2006-05       Impact factor: 9.461

7.  Determination of the functionality of common APOA5 polymorphisms.

Authors:  Philippa J Talmud; Jutta Palmen; Wendy Putt; Laurence Lins; Steve E Humphries
Journal:  J Biol Chem       Date:  2005-06-07       Impact factor: 5.157

8.  Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11.

Authors:  Michael Olivier; Xujing Wang; Regina Cole; Brian Gau; Jessica Kim; Edward M Rubin; Len A Pennacchio
Journal:  Genomics       Date:  2004-05       Impact factor: 5.736

9.  APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study.

Authors:  Philippa J Talmud; Steve Martin; Marja-Riitta Taskinen; M Heikki Frick; Markku S Nieminen; Y Antero Kesäniemi; Amos Pasternack; Steve E Humphries; Mikko Syvänne
Journal:  J Lipid Res       Date:  2004-01-16       Impact factor: 5.922

Review 10.  The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?

Authors:  Ko Willems van Dijk; Patrick C N Rensen; Peter J Voshol; Louis M Havekes
Journal:  Curr Opin Lipidol       Date:  2004-06       Impact factor: 4.776

View more
  27 in total

1.  Association of FURIN and ZPR1 polymorphisms with metabolic syndrome.

Authors:  Chikara Ueyama; Hideki Horibe; Yuichiro Yamase; Tetsuo Fujimaki; Mitsutoshi Oguri; Kimihiko Kato; Masazumi Arai; Sachiro Watanabe; Toyoaki Murohara; Yoshiji Yamada
Journal:  Biomed Rep       Date:  2015-06-29

2.  Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers.

Authors:  Qin Feng; Susan S Baker; Wensheng Liu; Ricardo A Arbizu; Ghanim Aljomah; Maan Khatib; Colleen A Nugent; Robert D Baker; Trudy M Forte; Yiyang Hu; Lixin Zhu
Journal:  Pathology       Date:  2015-06       Impact factor: 5.306

3.  Association of a genetic variant of the ZPR1 zinc finger gene with type 2 diabetes mellitus.

Authors:  Fumitaka Tokoro; Reiko Matsuoka; Shintaro Abe; Masazumi Arai; Toshiyuki Noda; Sachiro Watanabe; Hideki Horibe; Tetsuo Fujimaki; Mitsutoshi Oguri; Kimihiko Kato; Shinya Minatoguchi; Yoshiji Yamada
Journal:  Biomed Rep       Date:  2014-11-07

Review 4.  Apolipoprotein A5 fifteen years anniversary: Lessons from genetic epidemiology.

Authors:  Jaroslav A Hubacek
Journal:  Gene       Date:  2016-08-02       Impact factor: 3.688

5.  Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels.

Authors:  S F C Vaessen; G M Dallinga-Thie; C J D Ross; L J Splint; L W Castellani; P C N Rensen; M R Hayden; F G Schaap; J A Kuivenhoven
Journal:  J Lipid Res       Date:  2009-01-13       Impact factor: 5.922

Review 6.  Influence of apolipoprotein A-V on the metabolic fate of triacylglycerol.

Authors:  Vineeta Sharma; Trudy M Forte; Robert O Ryan
Journal:  Curr Opin Lipidol       Date:  2013-04       Impact factor: 4.776

7.  Association of apolipoprotein A5 concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men.

Authors:  Yae Jung Hyun; Yangsoo Jang; Jey Sook Chae; Ji Young Kim; Jean Kyung Paik; So Yeon Kim; Ju Young Yang; Jose M Ordovas; Young Guk Ko; Jong Ho Lee
Journal:  Atherosclerosis       Date:  2008-12-31       Impact factor: 5.162

8.  The ins (cell) and outs (plasma) of apolipoprotein A-V.

Authors:  Trudy M Forte; Xiao Shu; Robert O Ryan
Journal:  J Lipid Res       Date:  2008-12-02       Impact factor: 5.922

9.  Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans.

Authors:  Jon C Gonzales; Philip L S M Gordts; Erin M Foley; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2013-05-08       Impact factor: 14.808

10.  Determinants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans.

Authors:  P Hahne; F Krempler; F G Schaap; S M Soyal; H Höffinger; K Miller; H Oberkofler; W Strobl; W Patsch
Journal:  J Intern Med       Date:  2008-06-03       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.